Recessive Dystrophic Epidermolysis (RDEB) Pipeline Insight, 2020 - Therapeutic Assessment, Unmet Needs, Products, Drugs, Companies - ResearchAndMarkets.com

DUBLIN--()--The "Recessive Dystrophic Epidermolysis (RDEB) Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Recessive Dystrophic Epidermolysis (RDEB) market.

A detailed picture of the Recessive Dystrophic Epidermolysis (RDEB) pipeline landscape is provided, which includes the disease overview and Recessive Dystrophic Epidermolysis (RDEB) treatment guidelines. The assessment part of the report embraces in-depth Recessive Dystrophic Epidermolysis (RDEB) commercial assessment and clinical assessment of the Recessive Dystrophic Epidermolysis (RDEB) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recessive Dystrophic Epidermolysis (RDEB) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Recessive Dystrophic Epidermolysis (RDEB) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Recessive Dystrophic Epidermolysis (RDEB) treatment.
  • Recessive Dystrophic Epidermolysis (RDEB) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Recessive Dystrophic Epidermolysis (RDEB) market.

Scope of the Report

  • The Recessive Dystrophic Epidermolysis (RDEB) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Recessive Dystrophic Epidermolysis (RDEB) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Recessive Dystrophic Epidermolysis (RDEB) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Recessive Dystrophic Epidermolysis (RDEB) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Recessive Dystrophic Epidermolysis (RDEB).

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Recessive Dystrophic Epidermolysis (RDEB).
  • In the coming years, the Recessive Dystrophic Epidermolysis (RDEB) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Recessive Dystrophic Epidermolysis (RDEB) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Recessive Dystrophic Epidermolysis (RDEB) treatment market. Several potential therapies for Recessive Dystrophic Epidermolysis (RDEB) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Recessive Dystrophic Epidermolysis (RDEB) market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Recessive Dystrophic Epidermolysis (RDEB)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered


1. Report Introduction


2. Recessive Dystrophic Epidermolysis (RDEB)

2.1. Overview

2.2. History

2.3. Recessive Dystrophic Epidermolysis (RDEB) Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Recessive Dystrophic Epidermolysis (RDEB) Diagnosis

2.6.1. Diagnostic Guidelines


3. Recessive Dystrophic Epidermolysis (RDEB) Current Treatment Patterns

3.1. Recessive Dystrophic Epidermolysis (RDEB) Treatment Guidelines


4. Recessive Dystrophic Epidermolysis (RDEB) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Recessive Dystrophic Epidermolysis (RDEB) companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Recessive Dystrophic Epidermolysis (RDEB) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Recessive Dystrophic Epidermolysis (RDEB) Acquisition Analysis


5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target


6. Recessive Dystrophic Epidermolysis (RDEB) Late Stage Products (Phase-III)


7. Recessive Dystrophic Epidermolysis (RDEB) Mid Stage Products (Phase-II)


8. Early Stage Products (Phase-I)


9. Pre-clinical Products and Discovery Stage Products


10. Inactive Products


11. Dormant Products


12. Recessive Dystrophic Epidermolysis (RDEB) Discontinued Products


13. Recessive Dystrophic Epidermolysis (RDEB) Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table


14. Recessive Dystrophic Epidermolysis (RDEB) Key Companies


15. Recessive Dystrophic Epidermolysis (RDEB) Key Products


16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation


17. Recessive Dystrophic Epidermolysis (RDEB) Unmet Needs


18. Recessive Dystrophic Epidermolysis (RDEB) Future Perspectives


19. Recessive Dystrophic Epidermolysis (RDEB) Analyst Review

Companies Mentioned

  • Fibrocell Technologies, Inc.
  • Phoenix Tissue Repair, Inc.
  • Onconova Therapeutics, Inc.
  • Holostem Terapie Avanzate s.r.l.
  • Wings Therapeutics Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/6638oe.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900